Does PACB pay dividends?

Pacific Biosciences of California (PACB) does not currently pay a regular dividend.

What is PACB's market cap?

Pacific Biosciences of California (PACB) has a market capitalization of $435.16M with a current stock price of $1.35.

Pacific Biosciences of California (PACB)

Official site

HEALTHCARE • MEDICAL DEVICES • NASDAQ

$1.35

-0.05 (-3.21%)

Market Cap: $435.16M

Last updated: Sep 01, 2026 at 10:00 AM ET

Earnings

Performance (10Y)

Beat Rate

68%(27/40)

Avg Surprise

-1.04%

Streak

6 Q

Upcoming Estimates

Sep 30, 2026

EPS Consensus$-0.13

Range$-0.14 - $-0.11

6 analysts

EPS Revisions

30d

EPS Estimate Drift

90d ago$-0.13+3.5%

60d ago$-0.13+2.6%

30d ago$-0.13+2.0%

7d ago$-0.13+2.5%

Current$-0.13

Revenue Consensus

$39M

Range$37M - $41M

5 analysts

Dec 31, 2026

EPS Consensus$-0.13

Range$-0.14 - $-0.10

6 analysts

Revenue Consensus

$38M

Range$34M - $42M

5 analysts

Period	Reported	Est.	Range	Surprise	B/M	Analysts	Revisions	YoY
Dec 31, 2026Dec 26EST	-	$-0.13	$-0.14 - $-0.10	-	-	6	-	-
Sep 30, 2026Sep 26EST	-	$-0.13	$-0.14 - $-0.11	-	-	6	1 1 30d	-
Jun 30, 2026Jun 26	$-0.14	$-0.14	$-0.14 - $-0.12	+0.00%	Beat	5	2 1 30d	-7.7%
Mar 31, 2026Mar 26	$-0.12	$-0.13	$-0.17 - $-0.11	+7.69%	Beat	7	0 1 30d	+20.0%
Dec 31, 2025Dec 25	$-0.12	$-0.13	$-0.15 - $-0.12	+7.69%	Beat	8	0 1 30d	+40.0%
Sep 30, 2025Sep 25	$-0.12	$-0.16	$-0.16 - $-0.12	+25.00%	Beat	7	6 0 30d	+29.4%
Jun 30, 2025Jun 25	$-0.13	$-0.18	$-0.18 - $-0.14	+27.78%	Beat	9	2 0 30d	+35.0%
Mar 31, 2025Mar 25	$-0.15	$-0.19	$-0.20 - $-0.17	+21.05%	Beat	10	1 2 30d	+42.3%
Dec 31, 2024Dec 24	$-0.20	$-0.17	$-0.21 - $-0.11	-17.65%	Miss	10	1 1 30d	+25.9%
Sep 30, 2024Sep 24	$-0.17	$-0.21	$-0.30 - $-0.16	+19.05%	Beat	12	1 0 30d	+37.0%
Jun 30, 2024Jun 24	$-0.20	$-0.22	$-0.29 - $-0.19	+9.09%	Beat	13	No revisions (30d)	+23.1%
Mar 31, 2024Mar 24	$-0.26	$-0.26	$-0.32 - $-0.23	+0.00%	Beat	13	4 0 30d	+16.1%
Dec 31, 2023Dec 23	$-0.27	$-0.28	$-0.35 - $-0.24	+3.57%	Beat	15	2 1 30d	+27.0%
Sep 30, 2023Sep 23	$-0.27	$-0.29	$-0.66 - $-0.26	+6.90%	Beat	10	2 0 30d	+15.6%
Jun 30, 2023Jun 23	$-0.26	$-0.31	$-0.36 - $-0.29	+16.13%	Beat	11	No revisions (30d)	+23.5%
Mar 31, 2023Mar 23	$-0.31	$-0.33	$-0.39 - $-0.29	+6.06%	Beat	8	No revisions (30d)	+16.2%
Dec 31, 2022Dec 22	$-0.37	$-0.36	$-0.40 - $-0.34	-2.78%	Miss	8	No revisions (30d)	-23.3%
Sep 30, 2022Sep 22	$-0.32	$-0.33	$-0.36 - $-0.31	+3.03%	Beat	6	No revisions (30d)	-39.1%
Jun 30, 2022Jun 22	$-0.34	$-0.34	$-0.37 - $-0.24	+0.00%	Beat	6	2 0 30d	-61.9%
Mar 31, 2022Mar 22	$-0.37	$-0.32	$-0.33 - $-0.22	-15.63%	Miss	6	No revisions (30d)	+17.8%
Dec 31, 2021Dec 21	$-0.30	$-0.29	$-0.29 - $-0.28	-3.45%	Miss	6	1 0 30d	-150.0%
Sep 30, 2021Sep 21	$-0.23	$-0.24	$-0.24 - $-0.21	+4.17%	Beat	4	No revisions (30d)	-64.3%
Jun 30, 2021Jun 21	$-0.21	$-0.21	$-0.22 - $-0.18	+0.00%	Beat	5	1 0 30d	-40.0%
Mar 31, 2021Mar 21	$-0.45	$-0.31	$-0.34 - $-0.26	-45.16%	Miss	5	No revisions (30d)	-114.3%
Dec 31, 2020Dec 20	$-0.12	$-0.12	-	+0.00%	Beat	5	1 0 30d	-9.1%
Sep 30, 2020Sep 20	$-0.14	$-0.13	$-0.15 - $-0.13	-7.69%	Miss	5	1 0 30d	+17.6%
Jun 30, 2020Jun 20	$-0.15	$-0.18	$-0.23 - $-0.14	+16.67%	Beat	3	No revisions (30d)	-7.1%
Mar 31, 2020Mar 20	$-0.21	$-0.15	$-0.18 - $-0.14	-40.00%	Miss	4	No revisions (30d)	-31.2%
Dec 31, 2019Dec 19	$-0.11	$-0.14	$-0.18 - $-0.14	+21.43%	Beat	3	No revisions (30d)	+47.6%
Sep 30, 2019Sep 19	$-0.17	$-0.15	$-0.17 - $-0.13	-13.33%	Miss	4	No revisions (30d)	+10.5%
Jun 30, 2019Jun 19	$-0.14	$-0.14	$-0.19 - $-0.12	+0.00%	Beat	4	No revisions (30d)	+17.6%
Mar 31, 2019Mar 19	$-0.16	$-0.16	$-0.20 - $-0.13	+0.00%	Beat	5	No revisions (30d)	+20.0%
Dec 31, 2018Dec 18	$-0.21	$-0.13	$-0.15 - $-0.12	-61.54%	Miss	5	No revisions (30d)	-16.7%
Sep 30, 2018Sep 18	$-0.19	$-0.15	$-0.17 - $-0.13	-26.67%	Miss	7	No revisions (30d)	+0.0%
Jun 30, 2018Jun 18	$-0.17	$-0.17	$-0.18 - $-0.15	+0.00%	Beat	5	No revisions (30d)	+34.6%
Mar 31, 2018Mar 18	$-0.20	$-0.19	$-0.20 - $-0.18	-5.26%	Miss	6	No revisions (30d)	+23.1%
Dec 31, 2017Dec 17	$-0.18	$-0.20	$-0.21 - $-0.18	+10.00%	Beat	6	No revisions (30d)	+14.3%
Sep 30, 2017Sep 17	$-0.19	$-0.19	$-0.23 - $-0.18	+0.00%	Beat	6	No revisions (30d)	+0.0%
Jun 30, 2017Jun 17	$-0.26	$-0.24	$-0.26 - $-0.22	-8.33%	Miss	6	No revisions (30d)	-
Mar 31, 2017Mar 17	$-0.26	$-0.23	-	-13.04%	Miss	-	-	-
Dec 31, 2016Dec 16	$-0.21	$-0.23	-	+8.70%	Beat	-	-	-
Sep 30, 2016Sep 16	$-0.19	$-0.20	-	+5.00%	Beat	-	-	-

Key Metrics

Valuation
P/E Ratio	-2.71	EV/EBITDA	140.79x
Price/FCF	-3.41x	FCF Yield	-29.36%
Profitability
Profit Margin	-82.50%	Operating Margin	-114.40%
ROE	-929.00%	ROIC	-20.16%
Financial Health
Debt/Equity	-19.40x	Interest Coverage	-16.81x
Current Ratio	4.92x	Quick Ratio	4.03x
Trading Statistics
Beta	2.32	Avg Volume	7.73M
52-Week High	$2.73	52-Week Low	$1.07

Technical Indicators Dashboard

Moving Averages

SMA 10$1.37

SMA 20$1.28

SMA 50$1.41

SMA 200$1.64

EMA 10$1.38

EMA 20$1.35

EMA 50$1.37

EMA 200$1.50

MACD

Line: 0.02Signal: -0.01Hist: 0.03

ADX

ADX: 22.1+DI: 23.8-DI: 21.4

Aroon & PSAR

Aroon Up88.0

Aroon Down48.0

PSAR$1.28

Bollinger Bands

Upper Band$1.58

Lower Band$0.99

%B Position4571%(Upper)

Band Width0.62

RSI (14-Day)

Neutral

50.3

Momentum Oscillators

Stoch %K67.6

Stoch %D80.1

Williams %R-47.2

ROC (10d)12.0%

Momentum0.14

CCI (20d)48.6

MFI (14d)64.0

Volatility Measures

ATR (14d)$0.11(8.5%)

StdDev (20d)0.15

Hist Vol116.4%(High)

Volume Flow

VWAP$1.37

OBV-33.0M

AD Line-137.7M

CMF (20d)-0.123

Volume Metrics

Avg Vol (20d)7.9M

Vol Ratio0.8x

VWMA (20d)$1.29

Pivot Points

R3$1.66

R2$1.60

R1$1.50

Pivot Point$1.45

S1$1.34

S2$1.29

S3$1.19

Advanced Oscillators

TSI4.00

Ultimate Osc54.1

KST-51.53

Financial Data

Quarter	Jun 2026	Mar 2026	Dec 2025	Sep 2025	Jun 2025	Mar 2025	Dec 2024	Sep 2024	Jun 2024	Mar 2024	Dec 2023	Sep 2023
Total Revenue	$39.01M	$37.18M	$44.65M	$38.44M	$39.77M	$37.15M	$39.22M	$39.97M	$36.01M	$38.81M	$58.36M	$55.69M
Cost of Revenue	$26.37M	$24.34M	$28.08M	$22.54M	$25.08M	$38.52M	$29.17M	$29.96M	$30.07M	$27.53M	$48.79M	$37.79M
Gross Profit	$12.64M	$12.84M	$16.57M	$15.90M	$14.68M	$-1,371,000	$10.06M	$10.00M	$5.94M	$11.28M	$9.57M	$17.90M

Operating Expenses	$57.25M	$21.20M	$57.76M	$54.78M	$59.54M	$427.56M	$163.09M	$74.08M	$181.78M	$92.64M	$97.12M	$100.39M
R&D	$23.02M	$19.61M	$22.88M	$22.85M	$22.53M	$29.05M	$27.47M	$25.52M	$38.48M	$43.45M	$44.54M	$47.51M
SG&A	$33.39M	$31.15M	$34.05M	$31.10M	$36.17M	$40.17M	$41.64M	$43.75M	$45.88M	$43.75M	$46.00M	$43.43M
Operating Income	$-44,610,000	$-8,357,000	$-41,197,000	$-38,877,000	$-44,853,000	$-428,934,000	$-153,028,000	$-64,077,000	$-175,846,000	$-81,362,000	$-87,548,000	$-82,492,000

Interest Income	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0
Interest Expense	$2.11M	$1.74M	$1.74M	$1.74M	$1.74M	$1.74M	$-151,650,000	$3.54M	$3.54M	$3.58M	$3.57M	$3.59M
Income Before Tax	$-44,683,000	$-8,091,000	$-40,169,000	$-37,617,000	$-41,895,000	$-426,377,000	$2.69M	$-60,725,000	$-173,319,000	$-78,178,000	$-82,736,000	$-77,575,000
Income Tax Expense	$58,000	$184,000	$202,000	$383,000	$35,000	$-302,000	$316,000	$0	$0	$0	$-718,000	$-10,706,000

Net Income	$-44,741,000	$-8,275,000	$-40,371,000	$-38,000,000	$-41,930,000	$-426,075,000	$2.37M	$-60,725,000	$-173,319,000	$-78,178,000	$-82,018,000	$-66,869,000

EBITDA	$-37,757,000	$-2,577,000	$-34,240,000	$-32,399,000	$-33,869,000	$-53,567,000	$-140,395,000	$-44,179,000	$-159,029,000	$-66,620,000	$-70,218,000	$-72,507,000
EBIT	$-42,573,000	$-6,351,000	$-38,429,000	$-35,878,000	$-40,157,000	$-424,640,000	$-148,963,000	$-57,187,000	$-169,777,000	$-74,603,000	$-79,165,000	$-73,987,000

* Some calculated fields are derived from available data when not provided by source

Related GNG Research

No research available

Be the first to write about PACB

Government Contracts

Gov Obligations (TTM)

$2.22M

Gov Obligations / Revenue

1.4%

Obligations YoY

21.0%

Active Awards

New Awards (TTM)

Avg Remaining Term

10.9 mo

Top agency: Department of Agriculture at 51.8% of trailing twelve month obligations across 3 agencies

Recent Awards

Award ID	Agency	Obligated	Start	End	Description
75N98026P00928	Department of Health and Human ServicesNational Institutes of Health	$346907	Jul 8, 2026	Jul 7, 2027	NHGRI: SUPPLY: SEQUENCING REAGENTS: N/A
1232SA26F0221	Department of AgricultureAgricultural Research Service	$240216	Apr 29, 2026	Sep 30, 2026	LONG-READ SEQUENCING REAGENTS OF WHOLE GENOME ANALYSES
1232SA25F0277	Department of AgricultureAgricultural Research Service	$232854	Sep 24, 2025	Sep 30, 2026	PACBIO REAGENT KITS. ALL REAGENTS FOR SEQUENCING 24 REVIO SMRT CELLS QUANTITY 8, AND ASSOCIATED LIBRARY PREP REAGENTS.
75N92025P00381	Department of Health and Human ServicesNational Institutes of Health	$198083	Sep 16, 2025	Sep 26, 2026	REVIO SMRT CELLS AND SEQUENCING REAGENTS - NEW AWARD
1232SA25F0455	Department of AgricultureAgricultural Research Service	$194861	Sep 22, 2025	Jun 30, 2026	REVIO SPRQ REAGENT KIT, 24-PACK, PACIFIC BIOSCIENCES OF CALIFORNIA (NON-IT)
1232SA25F0317	Department of AgricultureAgricultural Research Service	$171500	Sep 3, 2025	Oct 3, 2025	VEGA BENCHTOP LONG READ SEQUENCER FROM PACIFIC BIOSCIENCES A LONG READ GENOMIC SEQUENCER THAT PROVIDES HIGH ACCURACY READS VIA SINGLE MOLECULE REAL TIME SEQUENCING THAT ARE 10-20KB IN LENGTH. BASE CALLING, DEMULTIPLEXING, AND FILE FORMATION ALL DO
75N98026P00331	Department of Health and Human ServicesNational Institutes of Health	$85000	Jul 25, 2026	Jul 24, 2027	THE NISC LABORATORY SUPPLIES STATE OF THE ART SEQUENCING SERVICES TO INSTITUTES THROUGHOUT THE NIH. THE HIGHLY ACCURATE LONG-READ SEQUENCE DATA PRODUCED BY THE PACBIO REVIO IS CRITICAL FOR CERTAIN TYPES OF EXPERIMENTS. THIS EQUIPMENT IS THEREFORE A V
1232SA26F0132	Department of AgricultureAgricultural Research Service	$85000	Jul 12, 2026	Jul 11, 2027	REVIO SERVICE CONTRACT - PRODUCT CODE 102-873-100 - SERIAL NUMBER 84124
75N92025P00290	Department of Health and Human ServicesNational Institutes of Health	$85000	Aug 1, 2025	Jul 31, 2026	SERVICE CONTRACT FOR PACIFIC BIOSCIENCES REVIO, NEW PO
1232SA26F0022	Department of AgricultureAgricultural Research Service	$83487	Dec 11, 2025	Dec 10, 2026	SERVICE CONTRACT FOR PACBIO REVIO

Federal contract obligations are bookings recorded by the awarding agency, not recognized revenue. They can exceed 100% of revenue and can be negative when contracts are de-obligated. Source: USAspending.gov prime awards, data through Jul 31, 2026.

News

PACB Stock Pops As New CEO Backs Powerful Vega Upgrade

Pacific Biosciences of California Inc. (PACB) stock surged by over 13% due to optimism surrounding its sequencing platform. The company announced a new CEO, Mark Van Oene, and a significant upgrade to its Vega benchtop sequencer, boosting data output and reducing costs. Despite ongoing financial losses, PACB's strong balance sheet and technological advancements are attracting active traders looking for momentum plays.

StocksToTrade•Aug 25, 2026 4:10 PM8/25/26•

Bullish

Chromosome level genome assembly and full-length transcriptome of blacktip trevally ( Caranx heberi )

This study presents the first high-quality chromosome-level genome assembly and full-length transcriptome of the blacktip trevally (Caranx heberi), a potential brackishwater aquaculture species. Researchers used PacBio HiFi reads, Illumina short reads, and Hi-C data to generate a 618.71 Mb genome with 24 chromosome-level scaffolds, along with transcriptomic data from seven tissues. These comprehensive genomic resources will aid in the domestication, aquaculture development, and further research into the species' nutritional potential, ecological adaptations, and evolutionary biology.

Nature•Aug 24, 2026 10:12 AM8/24/26•

Somewhat-Bullish

Pacific Biosciences of California, Inc. (NASDAQ:PACB) Given Average Recommendation of "Reduce" by Analysts

Analysts have given Pacific Biosciences of California, Inc. (NASDAQ:PACB) an average "Reduce" recommendation, with an average 12-month price target of $1.83, significantly higher than its opening price of $1.23. The company recently missed quarterly earnings expectations, reporting a loss of $0.14 per share against an estimated $0.13, and revenue of $39.01 million compared to $42.90 million expected. Despite the stock trading near its 12-month low, several institutional investors have increased their holdings.

MarketBeat•Aug 21, 2026 8:41 AM8/21/26•

Bearish

Pacific Biosciences CEO Mark van Oene sells $30,409 in stock

Pacific Biosciences CEO Mark van Oene sold 26,911 shares of the company's common stock for a total of $30,409. This transaction was to cover tax withholding obligations associated with restricted stock units. Following the sale, Van Oene directly holds over 2.7 million shares, while the company's stock trades near its 52-week low.

Investing.com•Aug 19, 2026 3:40 PM8/19/26•

Bearish

Pacific Biosciences CEO Mark van Oene sells $30,409 in stock

Pacific Biosciences CEO Mark van Oene sold 26,911 shares of company stock for $30,409 on August 17, 2026. This transaction was primarily to cover tax withholding obligations associated with the vesting of restricted stock units. The sale occurred as PACB stock trades near its 52-week low, and the company recently reported a revenue miss and adjusted its full-year outlook.

Investing.com•Aug 19, 2026 2:11 AM8/19/26•

Somewhat-Bearish

Frequently Asked Questions About PACB

Does PACB pay dividends?: Pacific Biosciences of California (PACB) does not currently pay a regular dividend.
What is PACB's market cap?: Pacific Biosciences of California (PACB) has a market capitalization of $435.16M with a current stock price of $1.35.

Get full access to GNG Research

Create a free account to access portfolio tracking, advanced tools, and more.

Create Free Account Log In